Alpha-Blockers As Colorectal Cancer Chemopreventive: Findings from a Case-Control Study, Human Cell Cultures, and In Vivo Preclinical Testing.

Autor:	Suzuki N; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. nsuzuki-ham@umin.ac.jp.; Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan.; School of Medicine, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia., Niikura R; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Ihara S; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan., Hikiba Y; Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan., Kinoshita H; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan., Higashishima N; Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan., Hayakawa Y; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Yamada A; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Hirata Y; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Nakata R; Department of Gastroenterology, Japanese Red Cross Medical Center, Tokyo, Japan., Okamoto M; Department of Gastroenterology, JR Tokyo General Hospital, Tokyo, Japan., Sano M; Department of Gastroenterology, Yaizu City Hospital, Shizuoka, Japan., Kushiyama A; Division of Diabetes and Metabolism, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan., Ichinose M; School of Medicine, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia., Woods SL; School of Medicine, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia., Worthley D; School of Medicine, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia., Iwamoto Y; Division of Diabetes and Metabolism, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan., Koike K; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Cancer prevention research (Philadelphia, Pa.) [Cancer Prev Res (Phila)] 2019 Mar; Vol. 12 (3), pp. 185-194. Date of Electronic Publication: 2019 Jan 30.
DOI:	10.1158/1940-6207.CAPR-18-0288
Abstrakt:	A retrospective case-controlled analysis was performed to identify drug candidates in the current use that may prevent colorectal cancer, outside of aspirin. A total of 37,510 patients aged ≥20 years were assessed to identify subjects who had been diagnosed with colorectal cancer by colonoscopy without a previous diagnosis of colorectal cancer, inflammatory bowel disease (IBD), or gastrointestinal symptoms; 1,560 patients were identified who were diagnosed with colorectal cancer by colonoscopy. The patients with colorectal cancer were matched with 1,560 age, gender, family history of colorectal cancer and comorbidity-matched control patients who were not diagnosed with colorectal cancer at colonoscopy. The medication histories were compared between the two groups. Next, candidate drugs that were more frequently used by the control patients were selected and their effects on human colorectal cancer cell lines in vitro and an inflammation-induced mouse model of colorectal cancer were tested. Putative colorectal cancer preventative agents were identified, including aspirin, vitamin D, vitamin B, vitamin C, vitamin E, xanthine oxidase inhibitor, alpha-blockers, angiotensin receptor blocker, nateglinide, probiotics, thienopyridine, folic acid, nitrovasodilators, bisphosphonates, calcium channel blockers, steroids, and statins ( P < 0.05). Alpha-blockers and xanthine oxidase inhibitors were selected for further study because these agents have not been analyzed previously as factors that may affect colorectal cancer outcomes. In vitro doxazosin (alpha-blocker), but not febuxostat (xanthine oxidase inhibitor), suppressed the proliferation of human colorectal cancer cells. Doxazosin also decreased tumorigenesis in an AOM/DSS mouse colorectal cancer model. Alpha-blockers may prevent colorectal cancer. (©2019 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu